Last reviewed: June 30, 2026

Last updated: June 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide is a GLP-1 receptor agonist originally developed to treat type 2 diabetes, but clinical trials have demonstrated its potent effect on appetite suppression and weight reduction in people without diabetes. The medication works by slowing gastric emptying and signaling fullness to your brain, leading to sustained calorie reduction without extreme dietary restriction. Understanding how dosing works—and how it differs from the original Ozempic diabetes formulation—helps you set realistic expectations for your weight loss journey.

How Semaglutide Dosing Typically Works for Weight Loss

Semaglutide for weight loss (branded as Wegovy when FDA-approved) follows a tiered dosing protocol designed to minimize side effects while building tolerance. The standard escalation schedule introduces the medication in small increments: Week 1–4 you receive 0.25 mg, Week 5–8 you move to 0.5 mg, Week 9–12 you reach 1 mg, and Week 13–16 you advance to 1.7 mg before reaching the maintenance dose of 2.4 mg weekly. This gradual approach allows your body to adapt to the medication and reduces the likelihood of severe nausea or gastrointestinal discomfort that can occur with rapid dose escalation.

Clinical trial data from the STEP program (Semaglutide Treatment Effect in People with obesity) showed that participants who completed the full 16-week titration protocol and maintained a 2.4 mg weekly dose achieved an average weight loss of 15% of their starting body weight over 68 weeks. Some patients experience meaningful weight reduction at lower maintenance doses—such as 1.7 mg or 2 mg weekly—and do not require the maximum 2.4 mg dose to reach their goals. Your optimal dose depends on factors including your starting weight, metabolic rate, gastrointestinal tolerance, and how your specific genetic pathways respond to GLP-1 receptor activation.

The Difference Between Ozempic and Semaglutide for Weight Loss

Ozempic is the brand name for semaglutide when prescribed to treat type 2 diabetes, and it is dosed at a maximum of 1 mg weekly—significantly lower than the weight loss formulation. The weight loss version (Wegovy) was developed with a higher maximum dose of 2.4 mg weekly after evidence showed that higher doses produced greater appetite suppression and metabolic benefits in people without diabetes. Both formulations contain the same active ingredient, but they are marketed and dosed differently based on their intended use and the clinical evidence supporting each dosing strategy.

Because the weight loss dose range extends beyond what is used for diabetes management, Ozempic prescriptions cannot be refilled as a substitute for a weight loss medication. Healthcare providers must write separate prescriptions for the weight loss formulation, and patients seeking this therapy should work with a provider experienced in GLP-1 weight loss protocols. PlexusDx compounded semaglutide injections are formulated and dosed specifically for weight management, starting at $149/month with a transparent flat-rate pricing model—your dose may increase, but your monthly cost does not.

Why Your Starting Dose and Titration Speed Matter

Not all patients tolerate the standard 4-week titration schedule equally well. Some individuals experience manageable nausea or appetite suppression from the first injection, while others report significant gastrointestinal side effects that improve only after several weeks. If you experience severe nausea, vomiting, or constipation during the early weeks of titration, your provider may recommend extending the time at each dose level—for example, remaining at 0.25 mg for 6–8 weeks instead of 4 weeks—to allow your body additional adaptation time. This personalized titration approach preserves the medication's efficacy while improving your quality of life during treatment.

Research indicates that individual genetic variations in GLP1R expression, GIPR sensitivity, and other peptide-pathway genes influence how quickly your body responds to semaglutide and how high a dose you ultimately need. The PlexusDx Precision Peptide Genetic Test analyzes 14 metabolic pathways and 150+ genetic insights to predict your likely dose tolerance and response pattern, allowing your provider to tailor your starting dose and titration speed before your first injection. This genetic personalization—unavailable through standard weight loss programs—reduces trial-and-error dosing and accelerates your path to an effective, well-tolerated maintenance dose.

Maintaining Your Weight Loss Dose: Long-Term Considerations

Once you reach a maintenance dose—whether that is 1.7 mg, 2 mg, 2.4 mg, or another level where you experience appetite control and steady weight loss—most patients remain on that same weekly dose for the duration of their treatment. Unlike some medications where tolerance develops and dose increases become necessary to maintain effect, semaglutide typically sustains its appetite-suppressing benefit at a stable dose. However, if your weight loss plateaus after several months at a consistent dose, your provider may discuss a modest dose increase or a combination therapy approach using PlexusDx GLP-Squared (a compounded dual-peptide product combining semaglutide and tirzepatide).

Weight regain after stopping semaglutide occurs in a significant proportion of users—clinical data shows that approximately 70% of weight loss is regained within one year of discontinuation. For this reason, semaglutide is best viewed as a long-term weight management tool rather than a short-term intervention. PlexusDx supports ongoing treatment with no membership fees, HSA/FSA eligibility for all injectable and oral formulations, and consistent monthly pricing regardless of your dose level. If you decide to adjust or discontinue semaglutide at any point, your PlexusDx provider can discuss alternative GLP-1 agents, peptide combinations, or a structured tapering plan to minimize rebound weight gain.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the typical starting dose of semaglutide for weight loss?

Semaglutide treatment for weight loss begins at 0.25 mg injected subcutaneously once weekly for the first 4 weeks, then escalates every 4 weeks until reaching a therapeutic maintenance dose of 1.7–2.4 mg weekly. Your starting dose and titration pace may be personalized based on your genetic profile when using PlexusDx Precision Peptide Genetic Test insights.

How much weight can I expect to lose on semaglutide?

Clinical trial data (STEP program) showed average weight loss of 15% of starting body weight over 68 weeks at the 2.4 mg maintenance dose. Some patients achieve 10–12% weight loss at lower doses. Individual outcomes vary based on genetics, adherence, diet, and activity level; PlexusDx genetic testing can help predict your likely response category.

Does PlexusDx increase my monthly cost if my dose goes up?

No. PlexusDx compounded semaglutide injections are priced at a flat monthly rate starting at $149/month—your cost remains the same whether your dose is 0.25 mg, 1 mg, or 2.4 mg weekly. This transparent pricing model eliminates dose-escalation anxiety and ensures predictable monthly expenses throughout your treatment.

What are the most common side effects during semaglutide dose escalation?

Nausea, vomiting, constipation, and loss of appetite are the most frequently reported side effects, especially during the first 4–8 weeks of treatment. Most side effects diminish as your body adapts to the medication. If side effects are severe, your provider may extend the time spent at each dose level to improve tolerance while maintaining efficacy.

How does the PlexusDx Precision Peptide Genetic Test help with semaglutide dosing?

The test analyzes your GLP1R, GIPR, FTO, MC4R, and 10 other genetic variants associated with peptide pathway sensitivity and weight regulation. These insights help your provider predict your likely dose tolerance, optimal maintenance dose range, and whether you may benefit from a faster or slower titration schedule—personalizing your treatment plan before you start injections.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves